{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:40:46Z","timestamp":1791434446905,"version":"4.3.3"},"reference-count":26,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13205","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:33:27Z","timestamp":1780914807000},"page":"1-10","source":"Crossref","is-referenced-by-count":2,"title":["Immune\u2011related nephritis, ureteritis and cystitis secondary to immune checkpoint inhibitors: A case report and review of the literature"],"prefix":"10.3892","volume":"32","author":[{"given":"Guangquan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Changzhou Tumor Hospital, Changzhou, Jiangsu 213032, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Cancer Hospital\/Jiangsu Institute of Cancer Research\/The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Changzhou Tumor Hospital, Changzhou, Jiangsu 213032, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Changzhou Tumor Hospital, Changzhou, Jiangsu 213032, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhi","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhou Tumor Hospital, Changzhou, Jiangsu 213032, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhou Tumor Hospital, Changzhou, Jiangsu 213032, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"key20260715092725_b1-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"key20260715092725_b2-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"issue":"e005493","key":"key20260715092725_b3-ETM-32-2-13205","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005493","article-title":"Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR\/MSI-H metastatic colorectal cancer","volume":"11","author":"Nasca","year":"2023","journal-title":"J Immunother Cancer"},{"key":"key20260715092725_b4-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: A pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"key20260715092725_b5-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20260715092725_b6-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"key20260715092725_b7-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s13691-017-0298-6","article-title":"A case of cystitis after administration of nivolumab","volume":"6","author":"Ozaki","year":"2017","journal-title":"Int Cancer Conf J"},{"key":"key20260715092725_b8-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): A multicentre, open-label, phase1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"key20260715092725_b9-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: Management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260715092725_b10-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"key20260715092725_b11-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"key20260715092725_b12-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"497.e1","DOI":"10.1016\/j.genhosppsych.2013.12.005","article-title":"Amisulpride and symptomatic bradycardia: A case report","volume":"37","author":"Huang","year":"2015","journal-title":"Gen Hosp Psychiatry"},{"issue":"1501415","key":"key20260715092725_b13-ETM-32-2-13205","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1501415","article-title":"Immune-related adverse events with renal colic as the main manifestation: A case report of sintilimab-induced ureteritis\/cystitis treated by ureteral stent and review of the literature","volume":"15","author":"Ji","year":"2024","journal-title":"Front Immunol"},{"issue":"60","key":"key20260715092725_b14-ETM-32-2-13205","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0166-5","article-title":"Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction","volume":"4","author":"Kanz","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"e000467","key":"key20260715092725_b15-ETM-32-2-13205","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: Incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"757069","key":"key20260715092725_b16-ETM-32-2-13205","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757069","article-title":"Case report: A case of sintilimab-induced cystitis\/ureteritis and review of sintilimab-related adverse events","volume":"11","author":"Tu","year":"2021","journal-title":"Front Oncol"},{"issue":"1051577","key":"key20260715092725_b17-ETM-32-2-13205","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051577","article-title":"Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review","volume":"13","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"key20260715092725_b18-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/1750743X.2024.2389761","article-title":"Case reports of immune-related cystitis and the antibody combination hypothesis","volume":"16","author":"Zhang","year":"2024","journal-title":"Immunotherapy"},{"issue":"1119020","key":"key20260715092725_b19-ETM-32-2-13205","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1119020","article-title":"Enhancing urinary tract infection diagnosis for negative culture patients with metagenomic next-generation sequencing (mNGS)","volume":"13","author":"Jia","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"1727822","key":"key20260715092725_b20-ETM-32-2-13205","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1727822","article-title":"Single-center experience with immune checkpoint inhibitor-related ureteritis and cystitis","volume":"16","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"key20260715092725_b21-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"key20260715092725_b22-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s10637-025-01563-2","article-title":"Clinical presentation of PD-1\/PD-L1 immune checkpoint inhibitors induced cystitis","volume":"43","author":"Xiao","year":"2025","journal-title":"Invest New Drugs"},{"key":"key20260715092725_b23-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/iju5.12532","article-title":"A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab","volume":"5","author":"Fukunaga","year":"2022","journal-title":"IJU Case Rep"},{"key":"key20260715092725_b24-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CJI.0000000000000484","article-title":"Recurrent cystitis associated with 2 programmed death 1 inhibitors: A rare case report and literature review","volume":"46","author":"Fan","year":"2023","journal-title":"J Immunother"},{"key":"key20260715092725_b25-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/21691401.2022.2131354","article-title":"Treatment-related adverse events of PD-1\/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: A meta-analysis","volume":"50","author":"Mi","year":"2022","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"key20260715092725_b26-ETM-32-2-13205","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:27:32Z","timestamp":1784096852000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,8]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13205","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}